Anzeige
Mehr »
Login
Montag, 02.08.2021 Börsentäglich über 12.000 News von 667 internationalen Medien
Patent-Riese schlägt zu! Auffällige Volumina ziehen Käufer an! Aktie geht steil!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DKCH ISIN: NL0012169213 Ticker-Symbol: QIA 
Xetra
30.07.21
17:42 Uhr
45,190 Euro
+1,120
+2,54 %
1-Jahres-Chart
QIAGEN NV Chart 1 Jahr
5-Tage-Chart
QIAGEN NV 5-Tage-Chart
RealtimeGeldBriefZeit
44,36044,51001.08.
44,44044,58030.07.
PR Newswire
674 Leser
Artikel bewerten:
(2)

Letter from Davidson Kempner to Supervisory Board of Qiagen

LONDON, June 15, 2021 /PRNewswire/ --

Lawrence A. Rosen (Chairman of the Supervisory Board)
Elizabeth E. Tallett (Supervisory Board Director)
Dr. Metin Colpan (Supervisory Board Director)
Stéphane Bancel (Supervisory Board Director)
Prof. Dr. Ross Levine (Supervisory Board Director)
Prof. Dr. Elaine Mardis (Supervisory Board Director)
Thomas Ebeling (Supervisory Board Director)
Dr. Toralf Haag (Supervisory Board Director)

Hulsterweg 82, 5912 PL Venlo, Netherlands

Dear Members of the Supervisory Board,

Davidson Kempner European Partners, LLP's ("DKP") funds remain a significant shareholder in Qiagen (the "Company") and are engaged with the Company, the Executive Management, the Supervisory Board as well as many industry leaders and advisors. Post the lapsed deal, DKP worked with consultants and advisers to help lay out a series of operational and strategic objectives that we believe would put the Company on a path to success. These objectives were communicated to Lawrence Rosen. A critical issue that we identified was the need for a new Chairman to improve corporate governance and rebuild trust with stakeholders.

We are pleased with the progress on the operational side and the Executive Management team, led by Thierry Bernard and Roland Sackers, has performed strongly in executing on these key objectives. In particular, setting and meeting expectations, driving growth in new products and increasing transparency through improved financial reporting. Despite the Executive Management team performing strongly and successfully meeting these objectives, the Company's share price continues to underperform and trades at a discount to its historic P/E trading range and that of its peers. We believe this to be a function of historic corporate governance issues and a discount for the level of trust and confidence in the effectiveness of the Supervisory Board.

Following the failed Thermo Fisher Scientific sales process in August 2020, we expressed to Mr. Rosen our strong belief that in order for the Company to realise its potential and address historic issues with regards to the effectiveness of the Supervisory Board, there was a need to appoint a new external Chairman. A new Chairman, with a strong & pedigreed executive healthcare background is necessary to guide the Company in the innovative, fast changing and dynamic healthcare industry it competes in. We had expressed to Mr. Rosen and the Board that this was necessary given Mr. Rosen's long tenure on the Board (8 years), his complete lack of executive healthcare experience and his intimate involvement in the series of multi-year governance shortcomings culminating in the failed sales process. We had hoped and expected Mr. Rosen to act as an interim Chairman and assist in the process of finding a suitable appointment. Unfortunately, Mr. Rosen chose to pursue a different approach, and retained his position as Chairman while turning down highly qualified candidates for the Chairman role. While we welcome the appointment of the two additional NEDs, who we believe are strong additions to the Supervisory Board, this does not go far enough in addressing the key governance concerns. Elizabeth E. Tallett has been on the Board for 10 years, was likewise intimately involved in the same multi-year governance shortcomings, has many other commitments and lastly, in her role on the Nomination Committee should not have allowed Mr. Rosen to unduly influence the search for a Chairman.

We believe appointing a new external Chairman with a strong executive healthcare background would go a long way in rebuilding trust and confidence, which will allow the Executive Management team's strong execution and improved performance and prospects to be properly reflected in the Company's valuation.

DKP intends to vote against the reappointment of Lawrence Rosen (Chairman) and Elizabeth E. Talett (Supervisory Board Director) at the upcoming Annual General Meeting of Shareholders ("AGM"). We understand other shareholders share our concerns and we encourage all shareholders to exercise their right and vote against Lawrence Rosen and Elizabeth E. Tallett.

cc: Risto Koivula (Partner)

For media enquiries:
Greenbrook
Andrew Honnor, Rob White, Fanni Bodri
Email: davidsonkempner@greenbrookpr.com
Tel: +44 (0) 20 7952-2000

QIAGEN-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.